Skip to Content

'
Eleni Andreopoulou, MD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Research Interests

Metastatic Breast Cancer

Drug Development

Early Phase Clinical Trials

Translational Research

Education & Training

Degree-Granting Education

1994 Medical School of Ioannina, Ioannina, Greece, MD, Internal Medicine

Postgraduate Training

2004-2007 Fellowship, Hematology/Oncology, NYU School of Medicine, New York, NY
2001-2004 ESMO Fellowship, Drug Development/Medical Oncology, Institute of Cancer Research/Royal Marsden Hospital, London, United Kingdom
1998-2001 Residency, Hematology, St. Bartholomew's Hospital, London, United Kingdom
1995-1998 Internship/Residency, Internal Medicine, University Hospital, Ioannina, Greece

Professional Memberships

American Association for Cancer Research (AACR)
Member, 2006-present
American Medical Association (AMA)
Member, 2006-present
American Society of Clinical Oncology (ASCO)
Member, 2006-present
European School of Oncology Club (ESO)
Member, 2006-present
European Society of Medical Oncology (ESMO)
Member, 2006-present
Southwest Oncology Group (SWOG)
Member, 2007-present
Translational Breast Cancer Research Consortium (TBCRC)
Member, 2006-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Andreopoulou E, Cristofanilli M. Circulating tumor cells (CTCs) as prognostic marker in metastatic breast cancer. FSG Expert Review of Anticancer Therapy. In Press.
2. Mego M, De Giorgi U, Broglio K, Dawood S, Valero V, Andreopoulou E, Handy B, Reuben JM, Cristofanilli M. Circulating tumor cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. Br J Cancer. In Press.
3. Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Andreopoulou E, Hall CS, Lodhi A, Jackson S, Lucci A. Detection of minimal residual disease in blood and bone marrow in early-stage breast cancer. Cancer. In Press.
4. De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol 27(20):3303-11, 7/2009. e-Pub 5/2009. PMID: 19451443.
5. Mego M, De Giorgi U, Hsu L, Ueno N, Valero V, Jackson S, Andreopoulou E, Kau SW, Reuben JM, Cristofanilli M. Circulating tumor cells in metastatic inflammatory breast cancer. Ann Oncol, 6/2009. e-Pub 6/2009. PMID: 19556320.
6. Andreopoulou E, Hortobagyi GN. Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy. J Clin Oncol 26(22):3660-2, 8/2008. PMID: 18669447.
7. Andreopoulou E, Muggia F.. Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanes. Clin Breast Cancer 8 Suppl 2:S54-60, 3/2008. PMID: 18637400.
8. Andreopoulou E, Gaiotti D, Kim E, Volm M, Oratz R Freedbert R, Downey A, Vogel CL, Chia S, Muggia F. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 7(9):690-6, 8/2007. PMID: 17919349.
9. Andreopoulou E, Yee H, Warycha MA, Macari M, Berman R, Lowy A, Muggia F.. Mucinous cancer of the appendix: challenges in diagnosis and treatment. J Chemother 19(4):451-4, 8/2007. PMID: 17855191.
10. Andreopoulou E, Gaiotti D, Kim E, Downey A, Mirchandani D, Hamilton A, Jacobs A, Curtin J, Muggia F. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol 18(4):716-21, 4/2007. e-Pub 2/2007. PMID: 17301073.
11. Andreopoulou E, Ross PJ, O'Brien ME, Ford HE, Priest K, Eisen T, Norton A, Ashley S, Smith IE. The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. Ann Oncol 15(9):1406-12, 9/2004. PMID: 15319247.
12. Andreopoulou E, Pectasidis D, Dimopoulos MA, Nikolaides C, fountzilas G, Valsami S, Economopoulos T.. Primary mediastinal large B-cell lymphoma: clinical study of a distinct clinical entity and treatment outcome in 20 patients: review of the literature. Am J Clin Oncol 27(3):312-6, 6/2004. PMID: 15170155.
13. Livi L, Andreopoulou E, Shah N, Paiar F, Blake P, Judson I, Harmer C.. Treatment of uterine sarcoma at the Royal Marsden Hospital from 1974 to 1998. Clin Oncol (R Coll Radiol) 16(4):261-8, 6/2004. PMID: 15214650.
14. Smith JA, Andreopoulou E.. An overview of the status of imaging screening technology for breast cancer. Ann Oncol 15(Suppl 1):l18-l26, 2004. PMID: 15280183.
15. Andreopoulou E, Andreopoulos D, Adamidis K, Fountzila-Kalogera A, Fountzilas G, Dimopoulos MA, Aravantinos G, Zamboglou N, Baltas D, Pavlidis N. Tumor volumetry as predictive and prognostic factor in the management of ovarian cancer. Anticancer Res 22(3):1903-8, May-Jun, 5/2002. PMID: 12168891.
16. Briasoulis E, Andreopoulou E, Tolis CF, Bairaktari E, Katsaraki A, Dimopoulos MA, Fountzilas G, Seferiadis C, Pavlidis N. G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting. Cancer 91(5):909-17, 3/2001. PMID: 11251942.
17. Kitsanou M, Andreopoulou E, Bai MK, Elisaf M, Drosos AA. Extensive lymphadenopathy as the first clinical manifestation in systemic lupus erythematosus. Lupus 9(2):140-3, 2000. PMID: 10787012.
18. Dimopoulos MA, Papadopoulou M, Andreopoulou E, Papadimitriou C, Pavlidis N, Aravantinos G, Aspropotamitis A, Anagnostopoulos A, Fountzilas G, Michalas S, Pectacides D. Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: A Hellenic Cooperative Oncology Group study. Gynecol Oncol 70(1):70-4, 7/1998. PMID: 9698477.
19. Fountzilas G, Athanassiades A, Giannakakis T, Briasoulis E, Bafaloukos D, Kalogera-Fountzila A, Onienaoum A, Kalofonos H, Pectasides D, Andreopoulou E, Bamia C, Kosmidis P, Pavlidis N, Skarlos D. A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study. Ann Oncol 8(12):1213-20, 12/1997. PMID: 9496386.
20. Kosmidis PA, Mylonakis N, Fountzilas G, Samantas E, Athanasiadis A, Andreopoulou E, Pavlidis N, Skarlos D. Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: a phase II study. Ann Oncol 8(7):697-9, 7/1997. PMID: 9296226.
21. Juul N, Eklund AC, Li Q, Burrell R, Valero V, Andreopoulou E, Esteva F, Symmans WF, Pusztai L, Szallasi Z, Swanton C. A functionally derived metagene predicts response to taxane-combination chemotherapy in primary breast cancer. Lancet Oncol. Submitted.
22. Michal M, De Giorgi U, Hsu L, Dawood S, Ueno NT, Valero V, Jackson S, Andreopoulou E, Reuben JM, Cristofanilli M. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Can Res. Submitted.

Invited Articles
1. Andreopoulou E, Cristofanilli M. Circulating tumor cells: Toward sophisticated approaches in managing metastatic breast cancer. Oncol 22(7), 6/2008.
2. Andreopoulou E, Cristofanilli C. Lapatinib monotherapy in inflammatory breast cancer: The story unfolds. Personalized Medicine Journal 5(3):211-13, 2008.
3. Andreopoulou E, Muggia FM. Chemotherapy of endometrial cancer: new ways of integrating anthracyclines, taxanes and platinums. Can Invest 24, 2006.

Editorials
1. Andreopoulou E, Hortobagyi GN. Overweight and smoking: Negative prognostic indicators. J Clin Oncol, Correspondence in Reply 27(7):1147-48, March 1, 2009.
2. Andreopoulou E, Hortobagyi GN. Prognostic factors in metastatic breast cancer: successes and challenges towards individualized therapy. J Clin Oncol 26(22):3660-2, 8/2008.
Other Articles
1. Kobrinski B, Andreopoulou E, Mourtzikos K, Muggia F. Diagnosis in Oncology: Documentation of complete response in metastatic breast cancer to liver and bone achieved with trastuzumab and pegylated liposomal doxorubicin. Clin Med Oncol 2:469-70, 6/2008.

Abstracts
1. Andreopoulou E, te Poele RH, Titley J, Cattini N, Clarke PA, Workman P. Relation between cytotoxicity, cell cycle phase distribution and global gene expression of platinum analogues in human colon cancer cell lines. Ann Oncol 13(Suppl 5):17, 10/2002.
2. Andreopoulou E, Ross PJ, O'Brien MR. The palliative benefits of MVP (mitomycin c, vinblastin and cisplatin) chemotherapy in patients with malignant mesothelioma. Lung Cancer 41(2):S218, 2003.
3. Andreopoulou E, Mourad M, Blank S, Reich E, Carapetyan K, Utate M, Muggia F, Smith J. Strategies for breast cancer screening and prevention in underserved minorities in the United States. The model of the Lynne Cohen Women's Clinic for high risk at Bellevue Hospital Center (BHC). Ann Oncol 15:216-17, 2004.
4. Andreopoulou E, Chen T, Liebes L, Lu J, Moore S, Fusco E, Liu P, Curtin J, Hochster H, Muggia F. Phase I/pharmacology study of intraperitoneal (IP) 3-5 day topotecan alone and with cisplatin: on day 1: potential for consolidation in ovarian cancer. J Clin Oncol 23:16S (#5045), 2005.
5. Andreopoulou E, Chen T, Liebes L, Curtin J, Hochster H, Muggia F. Topotecan (Topo)+/-cisplatin for intraperitoneal (IP) consolidation after platinum-based induction of epithelial ovarian cancer. Ann Oncol 17(9), 9/2006.
6. Andreopoulou E, Lowy A, Newman E, Downey A, Safa M, Escalon J, Hochster H, Mauro D, Muggia F. Cetuximab in mucinous peritoneal carcinomatosis: assessment by serial CA19.9 and CEA measurements. AACR, 3/2007.
7. Andreopoulou E, Ursin G, Carapetyan K, Utate M, Alvarez M, Muggia F, Smith F. Effects of letrozole on mammographic density (md) in post-menopausal (pm) women at high risk for breast cancer (BC). J Clin Oncol 25:18S (#1548), 2007.
8. Andreopoulou E, Urbauer DL, Krishnamurthy S, Reuben JM, Valero V, Cristofanilli M. and Fritsche HA. Comparison of circulating tumor cells (CTCs) in metastatic breast cancer (MBC): AdnaTest breast cancer for detection and biological characterization. Clin Can Res, 9/2008.
9. Andreopoulou E, Ueno N, Lichtiger B, Lara J, Hsu L, Vranas P, Woodward W, Lu A. Inflammatory Breast Cancer (IBC) and Blood Group Associations. Ann Oncol, 9/2008.
10. Yuan Q, Whitman GJ, Le-Petross HT, Cristofanilli M, Andreopoulou E, Jackson EF. Non-invasive 3.0T DWI, MRS, and DCE-MRI techniques for early assessing neoadjuvant chemotherapy in locally advanced breast cancer. RSNA Scientific Papers, SSQ01-03, 2008.
11. Gao H, Lucci A, Cohen EN, Lee BN, Li C, Krishnamurthy S, Andreopoulou E, Woodward WA, DeGiorgi U, Hortobagyi GN, Cristofanilli M, Reuben JM. Primary tumor size is associated with ALDH br breast cancer initiating stem cells in bone marrow aspirates of primary breast cancer patients. SABCS, Cancer Res 69 (Suppl 2) (#4031), 1/2009.
12. Cristofanilli M, DeGiorgi U, Rohren E, Ueno N, Miller C, Doyle G, Andreopoulou E, Handy B, Reuben J, Hortobagyi GN, Macapinlac H, Frotsche H, Valero V. Circulating tumor cells and FDG-PET/CT: Biological and functional methods for therapeutic monitoring in metastatic breast cancer (MBC). SABCS, Cancer Res 69(Suppl 2) (#6052), 1/2009.
13. Cohen EN, Jimenez C, Gao H, Lee B-N, Li C, Krishnamurthy S, Woodard WA, Andreopoulou E, Bethancourt DL, Hortobagyi GN, Cristofanilli M, Reuben JM. Immune cells from pleural fluids of patients with inflammatory breast cancer are immunocompetent. SABCS, Cancer Res 69 (Suppl 2) (#5044), 1/2009.
14. Andreopoulou E, Hatzis C, Booser D, Valero V, Wallace MJ, Sotiriou, Hortobagyi GN, Pusztai L, Symmans W. Estrogen receptor (ER) related genomic transcription significantly declines with increasing AJCC stage of ER-positive breast cancer, but ER gene expression does not. Suppl to J Clin Oncol, 2009 ASCO Ann Mtg Proc 27(15S, Part I of II):51s (#1044), 5/2009.
15. Robert F. Marschki, Andreopoulou E, Daniel D. Von Hoff, John K.C. Lim, Claire S. Padgett, Donald W. Northfelt. Phase I clinical trial of CX-4945: A first-in-class, orally administered small molecule inhibitor of protein kinase CK2. AACR-NCI-EORTC 2009. Submitted.

Last updated: 10/12/2009